Clovis Oncology Initiates Rolling NDA Submission to the FDA for Rociletinib in the Treatment of Advanced EGFR-Mutant Non-small Cell Lung Cancer
July 01, 2015 at 16:06 PM EDT
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that it has commenced the submission of a New Drug Application (NDA) regulatory ...
